#ESMO25: New evidence presented for #ADCs moving into the curative setting in #BreastCancer and #BladderCancer. Paolo Tarantino discusses the ‘unleashing’ of neoadjuvant and adjuvant ADC therapy to reduce recurrence and save lives
#ESMODailyReporter ➡️ https://ow.ly/vWqe50XeuTe

Paolo Tarantino, MD

#ESMO25: Clinically relevant survival benefits reported in platinum-resistant #OvarianCancer with pembrolizumab plus weekly paclitaxel with or without bevacizumab in ENGOT-ov65/KEYNOTE-B96 #ESMODailyReporter 👉https://ow.ly/MIjA50XeuR3

#immunotherapy

#ESMO25: Peri-operative enfortumab vedotin plus pembrolizumab significantly prolonged event-free and overall survival in cisplatin-ineligible patients with muscle-invasive #BladderCancer in the phase III KEYNOTE-905/EV-303 trial
#ESMODailyReporter➡️httpsef="https://ow.ly/YVy550XeuKH" class="hover:underline text-blue-600 dark:text-sky-400 no-card-link" target="_blank" rel="noopener" data-link="bsky">https://ow.ly/YVy550XeuKH

#ESMO25: Positive phase III #ClinicalTrial data with T-DXd in high-risk, HER2+ #EarlyBreastCancer suggest that a paradigm change in the treatment of these patients may be imminent.
Read more in the #ESMODailyReporter 📌 https://ow.ly/n1y050Xeuz0

#BreastCancer #ADC

#ESMO25: Disappointing results with #immunotherapy in head and neck cancer (#HNSCC) may be related to tumour heterogeneity. Sandra Schmitz considers how researchers can learn from disease biology to improve #ClinicalTrial design
#ESMODailyReporter 👉 https://ow.ly/EGlK50XesEz

#ESMO25: Thymus health appears to play a pivotal role in response to #immunotherapy. High vs low thymic health, assessed by an #AI-derived algorithm, was associated with improved survival in a cohort of patients treated with immunotherapy.
#ESMODailyReporter 👉 https://ow.ly/rk4P50XesEk

Data presented at #ESMO25 in extensive-stage #SCLC suggest new #ImmunoOncology combinations for first-line therapy (with tarlatamab) and maintenance treatment (with ceralasertib) may be on the horizon.
Read more in the #ESMODailyReporter 👉 https://ow.ly/Pwlf50XeswA

#LungCancer

#ESMO25: What is the clinical value of #GenomicProfiling in #RareCancers? Timothée Olivier discusses how comprehensive and prospective data are required to support wider implementation.
#ESMODailyReporter 👉 https://ow.ly/FwY550Xesut

#PrecisionOncology

#ESMO25: NorthStar #ClinicalTrial shows improved PFS with local consolidative therapy (LCT) added to osimertinib in metastatic EGFR-mutant #NSCLC, suggesting a role for LCT to extend disease control #ESMODailyReporter
👉https://ow.ly/V63o50Xe8Y7

#LungCancer

Results were presented at #ESMO25 from phase III #ClinicalTrials that highlighted both progress and ongoing challenges in the treatment of HER2-positive upper #GICancers.
Read more in the #ESMODailyReporter 🔗 https://ow.ly/SF7J50Xe3nK

#ESMO25: Is less more for patients with #GuCancers? Christoph Oing discusses promising treatment optimisation strategies to improve patient-centred endpoints and reduce therapy burden in #ProstateCancer and #UrothelialCancer.
#ESMODailyReporter 👉 https://ow.ly/hqih50Xe38b

#ESMO25: Lifetime Achievement Award recognises Rolf Stahel’s visionary leadership and enduring contributions to oncology, which have shaped research, education and international collaboration. More on his outstanding work.
#ESMODailyReporter 🔗 https://ow.ly/YMvx50XcYBP

#ESMO25: Glenda Ramos Martínez receives the first ESMO Oncologist of the Year Award for her pioneering role as the first female medical oncologist in Ecuador and outstanding advocacy to improve access to #CancerTreatments
#ESMODailyReporter👉 https://ow.ly/A3XL50XcYfo

#ESMO25: The 2025 ESMO Award for Translational Research recognises Christina Curtis groundbreaking contributions to cancer genomics and her pioneering role in translating complex data science into clinically meaningful insights
#ESMODailyReporter🔗 https://ow.ly/vY9R50XcXVV

Thierry Conroy receives the #ESMO25 Award in recognition of his remarkable contributions, particularly to the development of FOLFIRINOX for #PancreaticCancer and #RectalCancer and validation of #QoL assessment tools.
Read more in the #ESMODailyReporter 🔗 https://ow.ly/6HO850XcXO2

Deeply honoured for participating in #ESSO44 Gothenburg as speaker in the session Progress in Pseudomyxoma Peritonei Therapy! @essonews.bsky.social
To Berlin now for an exciting #ESMO25 @myesmo.bsky.social #ESMODailyReporter
and shortly see you at PSOGI meeting in Barcelona

🤖 Ensuring equitable access to oncology trials is a growing priority.📊 AI-enabled trials combined w/ an engagement and equity toolkit help reach diverse patients, reduce disparities & improve representation. #ESMODailyReporter dailyreporter.esmo.org/news/a-toolk...
#HealthAI #AIOncology #ESMOAI25

📊 Oncologists don’t need to be #AI experts, but they should understand how AI makes predictions and its limits. ESMO President Fabrice André calls for education & interdisciplinary collaboration to improve patient care.

#ESMODailyReporter 👉 buff.ly/wei558Y

#HealthAI #ESMOAI25

🤖 Multimodal foundation models integrate EHRs, genomics, imaging & patient-reported outcomes to help clinicians interpret #AIOncology
#ESMODailyReporter 👉 dailyreporter.esmo.org/news/ai-appl...
#DigitalOncology #ESMOAI25

🤖 Understanding #AI & patient-reported data is key in oncology. Remote patient monitoring gathers #RWD via apps & wearables. AI turns it into insights for earlier interventions & better care
#ESMODailyReporter 👉 sl1nk.com/qA8Vr

#HealthAI #DigitalOncology #ESMOAI25

🤖 What is the #EnvironmentalCost of #ArtificialIntelligence?

In his latest #ESMODailyReporter column, @pawelsobczuk.bsky.social discusses how the widespread use of AI tools is associated with high demand for energy, water & minerals.

🔗 buff.ly/VatevRB

#AIOncology #HealthAI #HealthData

#MAP2025: Umberto Malapelle describes how new technologies – #multiomic spatial profiling, #ctDNA analysis and #AI – can be integrated for a deeper understanding of cancer complexity.

Read more in the #ESMODailyReporter.

🔗 buff.ly/b26Mre7

#MAP2025: Two studies highlight T-cell dysfunction in pre-cancerous lesions, supporting targeted immune interception as a novel #immunotherapy approach.

Read more in the #ESMODailyReporter #TranslationalResearch

🔗 buff.ly/BKFC2yU

Epigenetic analyses provide valuable insights into early cachexia detection in #glioma and #OvarianCancer evolution after #NeoadjuvantChemotherapy as presented at #MAP2025.

Read more in the #ESMODailyReporter:
🔗 buff.ly/QBmPzJl

🤖 In the #ESMODailyReporter Charles Ferté discusses how AI and digital tools may play a crucial role in integrating the patient experience into the continuum of cancer care.

🔗 buff.ly/eVjxA8c

#AIOncology #HealthAI #HealthData #AIForPatients #PatientCare #ESMOAI25